Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SUGAR Study: SBRT and Relugolix for Prostate Cancer
NCT06111781Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Apr 2024
- Primary completion
- Feb 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 arms), sponsored by Yale University. Primary endpoint: Proportion of participants that attain PSA nadir up to 2 years. Started Apr 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06111781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111781.